0.25Open0.25Pre Close0 Volume25 Open Interest120.00Strike Price0.00Turnover0.00%IV51.21%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma981.76Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet